The second‐line study in advanced NSCLC with PD‐L1 >1% of pembrolizumab at 2 mg/kg and 10 mg/kg every 3 weeks compared with docetaxel had a median OS of 14.9 and 17.3 m from initiation of second‐line therapy.12 The gene discussed is CD274; the disease is non-small cell lung carcinoma.